A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia

NCT05579691 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
28
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Larimar Therapeutics, Inc.